PathoQuest Appoints Dr. Klaus Binder to Company’s Board of Directors
PathoQuest, the leading expert in GMP next-generation sequencing (NGS) services for biosafety testing, has announced that Klaus Binder, PhD has been appointed as a non-executive director to the PathoQuest board. Dr. Binder will provide insights and strategic guidance based on his large network with the biotech, pharma and life science industry and will also support PathoQuest in their efforts to expand business opportunities for drug discovery, corporate development, and product commercialisation.
Dr. Binder brings more than 30 years of experience in the Life Sciences industry, combining an understanding of therapeutic product development, technologies, and commercialization. He has a world-wide network based on relationships, successful projects and continuous interaction with companies in North America, Europe and Asia. Dr. Binder’s support for corporate development and M&A activities have benefited from both his technical understanding of the field and his visionary view on future needs of the industry.
Dr. Binder began his career as a biologist focusing on Research & Development at Boehringer Ingelheim in Germany. He subsequently took on roles in Business Development & Strategic Marketing at the company and became a member of the management team of the Biopharmaceutical Contract Manufacturing business for Boehringer. As Head of Corporate Business Development & Marketing he was responsible for the successful acquisition and world-wide branding of manufacturing sites in Germany and Austria with his responsibilities also including identification and evaluation of new manufacturing technologies. Subsequent to leaving Boehringer Ingelheim to focus on independently supporting biotech, pharma and life sciences technology companies drug discovery and corporate development/commercialisation initiatives, he has supported pre-clinical drug development, business development activities, the manufacture of large molecules as well as the commercialization of innovative technologies. He early on recognized that service business will become the major driver of life science industry and has leveraged his business development background to assist CDMOS and CROs build up their businesses.
“We are excited to add Dr. Binder to our Board of Directors since his global experience in the industry will further strengthen our efforts with biopharmaceutical manufacturer” stated Rainer Metzger, Chairman of PathoQuest’s Board of Directors. “His knowledge of the industry and networking capabilities will support our efforts to grow and expand our leadership position associated with the use of NGS for biosafety testing under GMP and non-GMP conditions.”
With over 20 peer reviewed publications on NGS applications in biosafety testing, PathoQuest is a leading expert in the application of Good Manufacturing Practices (GMP)-compliant next generation sequencing (NGS)-based biosafety testing. PathoQuest offers biopharmaceutical companies a game-changing genomic approach to ensuring the safety of biologics such as cell and gene therapy products, vaccines, and recombinant drugs, ultimately enabling a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines NGS platforms with proprietary sample preparation and data analysis processes to bring novel solutions to the industry. PathoQuest, headquartered in Paris, France, with a US based site in Wayne (PA) has worked with over 100 of the leading biopharmaceutical companies globally.